Driving pressure and adjunctive therapies in pulmonary sequelae of COVID-19 patients under invasive ventilation
Intensive Care Medicine · 2023
DOI: 10.1007/s00134-022-06951-3 ↗Kurz gefasst
Leserbrief in der Zeitschrift Intensive Care Medicine, 2023. Verfasst von Jessica González und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonary Department, Translational Research in Respiratory Medicine, University Hospital Arnau de Vilanova and Santa Maria, IRBLleida, Av. Alcalde R…. Hauptthemen laut MEDLINE: COVID-19, Noninvasive Ventilation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Instituto de Salud Carlos III.
Abstract (Originalsprache)
A non-negligible proportion of critical patients affected by coronavirus disease 2019 (COVID-19) and with acute respiratory distress syndrome (ARDS) need invasive mechanical ventilation (IMV) [1]. This population is most at risk of developing respiratory sequelae after hospital discharge, most commonly represented as impairment of carbon monoxide diffusing capacity (D LCO ) [2]. Predictive factors of lung diffusing capacity (D LCO ) impairment after IMV due to COVID-19 are unknown. This is a multicentre, prospective observational study in 51 Spanish intensive care units (ICUs). A total of 861 consecutive COVID-19 patients (confirmed by polymer-ase chain reaction) who underwent IMV from March 2020 to July 2021 and survived were included. At hospital admission, we collected sociodemographic, anthropo-metric, comorbidity, and lifestyle data. Moreover, in-hospital clinical and biological parameters, ventilatory parameters, and adjunctive therapies at three IMV time points (day one, three and the last day), and lung function and computed tomography findings at follow-up were assessed. Material and methods as well as statistical analysis are shown in electronic supplementary material (ESM). The median (p 25 –p 75 ) time from discharge to follow-up was 3.5 (2.7–4.7) months. The median age was 61 (53–67) years, and 26.9% were women. The mean (SD) percentage of predicted D LCO at follow-up was 70.3% (18%)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Pulmonary Department, Translational Research in Respiratory Medicine, University Hospital Arnau de Vilanova and Santa Maria, IRBLleida, Av. Alcalde Rovira Roure, 80, 25198, Lleida, Spain.
- CIBER of Respiratory Diseases (CIBERES), Institute of Health Carlos III, Madrid, Spain.
- Department of Pneumology, Hospital Clinic of Barcelona, August Pi i Sunyer Biomedical Research Institute-IDIBAPS, University of Barcelona, Barcelona, Spain.
- Pulmonary Department, Translational Research in Respiratory Medicine, University Hospital Arnau de Vilanova and Santa Maria, IRBLleida, Av. Alcalde Rovira Roure, 80, 25198, Lleida, Spain. febarbe.lleida.ics@gencat.catfe…
- CIBER of Respiratory Diseases (CIBERES), Institute of Health Carlos III, Madrid, Spain. febarbe.lleida.ics@gencat.catfebarbe.lleida.ics.
ORCID-Profile: Ferran Barbé
Förderung
- Instituto de Salud Carlos III
Zitieren
APA
González, J., Benítez, I. D., Motos, A., Torres, A., Barbé, F., & CIBERESUCICOVID Group (2023). Driving pressure and adjunctive therapies in pulmonary sequelae of COVID-19 patients under invasive ventilation. Intensive Care Medicine. https://doi.org/10.1007/s00134-022-06951-3
Vancouver
González J, Benítez ID, Motos A, Torres A, Barbé F, CIBERESUCICOVID Group. Driving pressure and adjunctive therapies in pulmonary sequelae of COVID-19 patients under invasive ventilation. Intensive Care Medicine. 2023. doi:10.1007/s00134-022-06951-3
BibTeX
@article{Gonzlez2023,
author = {González, Jessica and Benítez, Iván D and Motos, Anna and Torres, Antoni and Barbé, Ferran and CIBERESUCICOVID Group, CIBERESUCICOVID Group},
title = {Driving pressure and adjunctive therapies in pulmonary sequelae of COVID-19 patients under invasive ventilation},
journal = {Intensive Care Medicine},
year = {2023},
doi = {10.1007/s00134-022-06951-3}
}
EUVIMED